Abstract 5614
Background
Highly myelosuppressive chemotherapy (HMC) is the standard treatment for several types of sarcoma. Severe neutropenia is a common adverse event, which can lead to febrile neutropenia (FN) and major infections requiring hospitalization, with up to 15% mortality rate. Several trials showed an equal efficacy of filgrastim (F) and Peg-filgrastim (Peg-F) for preventing FN in many cancer types, but limited evidence is available in adult sarcoma patients (pts). We retrospectively compared the incidence of FN and hospitalization due to neutropenic infections in sarcoma pts treated with HMC with the support of either F or Peg-F.
Methods
We reviewed data of pts consecutively treated in our institution from Sep 2014 to Mar 2019. Inclusion criteria were: age >18 years; diagnosis of soft tissue sarcoma; at least 1 cycle of HMC supported by prophylactic F or Peg-F. Included HMC regimens were: doxorubicin ≥60 mg/m² (D) + ifosfamide ≥9 g/m² (IFO) +/- vincristine; high-dose IFO (≥12 g/m); IFO ≥9 g/m² + etoposide. Neutropenia prophylaxis included F (5-7 doses) or Peg-F (1 dose) according to physician‘s choice. χ2-Test was used to compare the outcomes; p ≤ 0.05 was considered significant.
Results
79 pts were found eligible, receiving 330 cycles of HMC. F and peg-F were used as prophylaxis in 66.6% (n = 220) and 33.3% (n = 110) of cases, respectively. The rate of FN was higher in the Peg-F group compared to the F group (11.8% vs 6.8, p = 0.12), while the rate of cycles complicated by a hospitalization was 9% and 3.2% (p = 0.02), respectively. 8/16 hospitalizations were due to pneumonia. One death during hospitalization occurred in the Peg-F group. 70% of hospitalizations occurred in metastatic pts, whereas 30% occurred during adjuvant treatments.
Conclusions
The use of peg-F was associated with a significantly higher rate of neutropenic infections requiring hospitalization compared with F in adult sarcoma pts receiving HMC. FN rate was numerically higher in pts receiving peg-F, not reaching statistical significance. These data suggest that F prophylaxis may be preferred in this setting to peg-F. Overall, prophylaxis with both agents provided a relatively low rate of hospitalizations and FN, compared with the myelosuppressive potential of the regimens.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5037 - CXCR4, CCR2 and CCR5 expression in subsets of tumor cells with stem and/or EMT features
Presenter: Olga Savelieva
Session: Poster Display session 1
Resources:
Abstract
5729 - Expression of mutant p53 affects cancer cell sensitivity to topotecan
Presenter: Rimma Mingaleeva
Session: Poster Display session 1
Resources:
Abstract
5725 - Breast cancer organoids a new tool for the prediction of drugs penetration and patient’outcome
Presenter: Giuseppina Roscigno
Session: Poster Display session 1
Resources:
Abstract
5680 - Aptamer-mediated exosomes detection for early breast cancer identification.
Presenter: Cristina Quintavalle
Session: Poster Display session 1
Resources:
Abstract
2460 - MicroRNA-181c promotes tamoxifen resistance in breast cancer cells via upregulation Akt/mTOR axis
Presenter: Alexander Scherbakov
Session: Poster Display session 1
Resources:
Abstract
3751 - Spatio-temporal separation of tumor infiltrating CD8+ T-cells and HER2/neu+ tumor cells in tumor-immune milieu of infiltrating ductal carcinoma of the breast
Presenter: Sandhya Sreedharan
Session: Poster Display session 1
Resources:
Abstract
4664 - Large genomic rearrangements in BRCA1 and BRCA2 genes in the Portuguese population.
Presenter: Joao Pinto
Session: Poster Display session 1
Resources:
Abstract
4611 - Non-BRCA1/2 hereditary breast and ovarian cancer: findings from a multidisciplinary program
Presenter: Ana Monteiro
Session: Poster Display session 1
Resources:
Abstract
5340 - Quantitative imaging and characterization of collagen patterns in high grade serous ovarian carcinoma (HGSOC)
Presenter: Ruby Huang
Session: Poster Display session 1
Resources:
Abstract
4209 - Semiquantitative assessment of vimentin expression in prostate cancer (PC)
Presenter: Marina Puchinskaya
Session: Poster Display session 1
Resources:
Abstract